"Our findings show that even common diseases can have a very exact genetic basis. Importantly, now that we know the cause of fibroadenoma, this research can have many potential applications. For example, measuring the MED12 gene in breast lumps may help clinicians to distinguish fibroadenomas from other types of breast cancer. As MED12 gene mutations are seen in the majority of benign fibroadenomas and are hardly [ever] found in cancers, their presence in a breast tumor may be able to corroborate benignity."
Tan Puay Hoon, head of the Department of Pathology, Singapore General Hospital, who is a member of a multidisciplinary research team that has made a significant breakthrough in the understanding of the molecular basis of benign fibroadenomas, one of the most common breast tumors in women

"The company's done a very good job of designing well-conducted phase II studies that give clear-cut answers and avoid the investment of larger amounts of money in later-stage clinical trials, only to be disappointed prior to NDA submission."
Stephen Hill, president and CEO of Targacept Inc., discussing the decision to halt development of TC-5214 in the treatment of overactive bladder following a phase II miss

"We have not looked at the public markets because we were more focused on the acquisition of Vivotif, because that gives us profitability. That means long-term sustainability, which is better than doing a single capital raise."
Kenneth Kelley, CEO of Paxvax Inc., discussing the acquisition of FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG, which the Redwood City, Calif.-based company financed with $50 million in secured debt from an investment fund managed by Pharmakon Advisors and a $12 million extension of its series B preferred stock